¹**Genome-wide insights into the shared genetic landscape between metabolic**

- ⁸ Institute for Liver Diseases of Anhui Medical University, Hefei, China.
- $\frac{9}{10}$ ⁹ These authors contributed equally to this work.
- 25 10 Lead Contact.
-

²⁷***Corresponding author:**

- ²⁸Meixiao Zhan MD, PhD
- 29 Professor
- ³⁰Guangzhou First Pepople's Hospital, the Second Affiliated Hospital, School of
- 31 Medicine, South China University of Technology, Guangzhou, 510006, China.
- ³²Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and
- ³³Treatment, Zhuhai People's Hospital, Zhuhai Clinical Medical College of Jinan
- ³⁴University, Zhuhai, 510009, China.
- 35 Tel:+86-(020)81048319
- ³⁶Email: zhanmeixiao@ext.jnu.edu.cn
- 37
- 38 Yuliang Feng MD, PhD
- ³⁹Associate Professor
- 40 Department of Pharmacology, School of Medicine; Southern University of Science
- 41 and Technology, Shenzhen, Guangdong, 518055, China.
- ⁴²Tel:+86 (755)-88012564
- ⁴³Email: fengyl@sustech.edu.cn
-

- 45 Tao Xu PhD
- 46 Professor
- ⁴⁷Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui
- ⁴⁸Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei,
- ⁴⁹230032, China.
- 50 Institute for Liver Diseases of Anhui Medical University, Hefei, 230032, China.
- 51 Tel: $+86 (0551) 65172131$
- 52 Email: xutao@ahmu.edu.cn
- 53
- 54 Wen Su MD, PhD
- ⁵⁵Associate Professor
- 56 Department of Pathophysiology, Shenzhen University Health Science Center,
- 57 Shenzhen University, Shenzhen, 518071, China.
- 58 Tel:+86 18188610625
- 59 Email: suwen@szu.edu.cn
- 60

- ⁶¹**Keywords:** Metabolic dysfunction-Associated fatty liver disease, Cardiovascular
- ⁶²diseases, genome-wide association studies, Shared genetic architectures, Genetic
- 63 pleiotropy.
-
- ⁶⁵Abstract: 275 words
- ⁶⁶Electronic word count manuscript: 4,568 words
- ⁶⁷Main figures and tables: 4 main figures, 1 main tables
- 68 Supplementary material: 2
- 69

⁷⁰**Conflict of interest statement**

- 71 All authors declare no competing interests.
- 72

⁷³**Financial support statement**

This study was supported by the Natural Science Foundation of China Excellent Young Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and Applied Basic Research Foundation for Distinguished Young Scholars (Grant no. 2024B1515020047), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research General Projects of Shenzhen Science and Technology Innovation Commission (Grant 79 no. JCYJ20230807093514029) (To Y.F.), Shenzhen University 2035 Program for Excellent Research 8690200000314, the Shenzhen Science and Technology Fund for 81 Distinguished Young Scholars (RCYX20231211090127031) (to W. S.), National 82 Natural Science Foundation of China (Grant no. 82230067, 82272103), the

91

⁹²**Author contributions**

93 J.Q., M.C., M.C., Y.F., and M.Z. as conceptualization and supervised this project and 94 wrote the manuscript. W.X., W.M., T.Y., Q.Z., and K.Y. performed the main analyses 95 and wrote the manuscript. X.Y, Q.Y., J.X., and X.H. performed the statistical analysis 96 and assisted with interpreting the results. W.S., T.X., Y.F., and M.Z. provided expertise 97 in cardiovascular biology and GWAS summary statistics. All authors provided 98 intellectual content and approved the final version of the manuscript.

⁹⁹**Abstract**

¹⁰⁰**Background& Aims**:Multiple epidemiological studies have suggested an association 101 between Metabolic dysfunction-associated fatty liver disease (MAFLD) and 102 cardiovascular diseases (CVDs). However, the genetic components that are shared 103 between the two remain unclear.

¹⁰⁴**Methods:** This genome-wide pleiotropic association study integrated comprehensive 105 genome-wide association studies (GWAS) summary data from publicly available 106 sources within European populations. It employed a range of genetic approaches to 107 analyze the shared genetic architectures between MAFLD and six CVDs: atrial 108 fibrillation (AF), coronary artery disease (CAD), venous thromboembolism (VTE), 109 heart failure (HF), peripheral artery disease (PAD), and stroke. Initially, we examined 110 the genetic correlation and overlap between these conditions. Subsequently, ¹¹¹Mendelian Randomization (MR) analysis was conducted to investigate potential 112 causal relationships. Finally, we explored horizontal pleiotropy at the levels of single ¹¹³nucleotide polymorphisms (SNPs), genes, and biological pathways to further 114 elucidate the shared genetic mechanisms underlying.

¹¹⁵**Results:** We observed significant genetic associations between MAFLD and four ¹¹⁶CVDs, including CAD, HF, PAD, and VTE. However, we noted extensive genetic 117 overlap in all but MAFLD-AF. MR analysis established causal relationships from ¹¹⁸MAFLD to both AF and PAD. Regarding horizontal pleiotropy, 49 pleiotropic loci 119 were identified at the SNP level with functional annotations, 13 demonstrating strong 120 evidence of colocalization. At the gene level, 14 unique pleiotropic genes were found,

 $\overline{6}$

128

¹²⁹**Impact and implications**

¹³⁰Metabolic dysfunction-associated fatty liver disease (MAFLD) has reached a 131 prevalence of 25-30% worldwide and has emerged as a global leading cause of ¹³²liver-related morbidity and mortality. Studies have shown that people with MAFLD ¹³³have a higher risk of cardiovascular disease (CVD) than the general population and 134 there is currently no effective drug to treat the comorbidity of the two, which imposes 135 a burden on the socioeconomic situation and the adverse effects are still rising. 136 Therefore, it is critical to understand how MAFLD affects CVD. Our study provides 137 unique insights into the mechanisms of comorbidity between MAFLD and CVD. The 138 increasing number of complications has prompted us to explore new treatment options, 139 so our study has important clinical significance.

140

¹⁴¹**Graphical abstract**

143

¹⁴⁴**Highlights:**

- 145 The first comprehensive and systematic study to explore the common genetic
- 146 components between MAFLD and CVD.
- 147 MAFLD and CVDs share genetic architectures and mechanisms.
- 148 Genetically predicted MAFLD increases the risk of AF and PAD.
- 149 The effects of SAMM50 (located at 22q13.31) on lipid metabolism support the
- 150 comorbidity of MAFLD and CVDs.
- 151 The localization of lipid droplet related contact site proteins to the membrane
- 152 plays a key role in the comorbidity of MAFLD and CVD.

Introduction

197 comorbidities of MAFLD and CVDs, as well as identify biological pathways offering 198 therapeutic promise.

²⁰⁰This study aims to uncover their genetic overlap beyond the genetic correlation 201 between MAFLD and six major CVDs—atrial fibrillation (AF), CAD, VTE, HF, 202 peripheral artery disease (PAD), and Stroke—by leveraging unprecedentedly large ²⁰³GWAS summary data from European ancestry. We applied the genetic analysis 204 incorporating pleiotropy and annotation (GPA), which estimates the total number of 205 unique and shared genetic variants between pairs of traits. The relevance of mixed 206 effects has been further emphasized by Local Analysis of [co]Variant Annotation ²⁰⁷(LAVA), which calculates local genetic correlations across the genome, even in the 208 presence of minimal r_g . Given that GPA and LAVA quantify total genetic overlap but 209 cannot pinpoint shared genomic loci, we subsequently utilized the Pleiotropic ²¹⁰Analysis under a Composite Null Hypothesis (PLACO) method to discover loci 211 jointly associated with MAFLD and each CVD beyond genome-wide significance, a 212 critical step for gaining biological insights. Additionally, we also utilize Latent 213 Heritable Confounder Mendelian randomization (LHC-MR) analyses to explore 214 potential causal relationships between MAFLD and CVDs, considering sample 215 overlap, bidirectional causal associations, and unobserved heritable confounders. 216 Together, these methods augment the insights gained from genetic correlation ²¹⁷analyses, shedding light on the distinct and common genetic frameworks 218 underpinning MAFLD and CVDs, with implications for how we conceptualize

219 genetic risk for the comorbidity between MAFLD and CVDs.

220

²²¹**Materials and methods**

²²²**Data sources and quality control**

²²³Genetic associations with MAFLD were derived from the largest genome-wide ²²⁴meta-analysis to date, involving 8,434 cases and 770,180 controls from four European 225 cohorts: the Electronic Medical Records and Genomics (eMERGE) Network, the UK 226 Biobank (UKB), the Estonian Biobank (EstBB), and the FinnGen Consortium, of ²²⁷which the diagnosis was determined based on the electronic health records of all 228 participants¹⁶. To ensure that the sample size is large enough to produce reliable 229 results, we use GWAS summary data from studies with sample sizes greater than ²³⁰50,000. Accordingly, our study encompassed six major CVDs, including AF, CAD, 231 VTE, HF, PAD, and Stroke. Specifically, GWAS summary statistics for AF were 232 retrieved from a recent meta-analysis of six cohorts, including the Health Study ²³³Nord-Trøndelag (HUNT), deCODE, Michigan Genome Initiative (MGI), DiscovEHR, ²³⁴UKB, and AFGen consortium, comprising 60,620 cases and 970,216 controls of 235 European ancestry¹⁷. GWAS summary statistics for CAD were extracted from a 236 genome-wide meta-analysis by the CARDIoGRAMplusC4D and UKB consortium, 237 including $181,522$ cases and $984,168$ controls of European ancestry¹⁸. GWAS 238 summary statistics for VTE were collected from the largest meta-analysis of seven cohorts to date, including 81,190 cases and 1,419,671 controls of European ancestry¹⁹. 240 GWAS summary data for HF were derived from the Heart Failure Molecular

248

249 Quality control was carried out strictly for GWAS summary data per the following 250 steps before further analysis:(i) alignment with the hg19 genome assembly, and the 251 1000 Genomes Project v3 Europeans was used as the reference²³; (ii) only including 252 autosomal SNPs; (iii) SNPs with duplicate entries or missing rsIDs were eliminated; ²⁵³(iv) SNPs with a minor allele frequency (MAF) value of 0.01 or less were excluded. ²⁵⁴To ensure robust results, we normalized the GWAS summary data for all phenotypic 255 SNPs, yielding 6,479,654 common SNPs across all diseases.

256

²⁵⁷**Assessing the genetic correlates of MAFLD and CVDs**

²⁵⁸We employed cross-trait linkage disequilibrium score regression (LDSC) analyses to assess the genetic correlation (r_e) between MAFLD and six major CVDs²⁴. LDSC, an 260 effective method for evaluating genetic correlations across the genome, utilizes the 261 linkage disequilibrium (LD) structure to estimate individual SNP effect sizes from 262 GWAS summary statistics²⁵. The method involves regression of these GWAS 263 summary statistics against LD scores derived from the European 1000 Genomes ²⁶⁴Project, minimizing biases related to polygenicity, sample overlap, and population 265 stratification²⁴. Due to its complexity, the major histocompatibility complex (MHC) 266 region was excluded from our analysis. First, univariate LDSC was conducted to 267 determine the SNP-based heritability (h^2_{SNP}) for MAFLD and each CVD. 268 Subsequently, bivariate LDSC estimated the r_g between MAFLD and CVDs by 269 performing a weighted linear regression on the product of Z-scores for MAFLD and ²⁷⁰CVDs against the LD scores for all available genetic variants. This approach provides 271 an unbiased estimate of r_g and reliably measures genetic correlations even in 272 overlapping samples between GWAS datasets. Genetic correlations rang from -1 to $+1$, 273 with values closer to the extremes indicating stronger influences, and negative values 274 suggest opposite-direction effects, while positive values indicate the same direction. 275 P-values below a Bonferroni-corrected significance threshold $(P = 0.05 / 6 = 8.3 \times 10^{-3})$ 276 were considered statistically significant.

277

278 To identify tissues closely associated with genetic susceptibility SNPs for MAFLD 279 and CVDs, we used LDSC applied to specifically expressed genes $(LDSC-SEG)^{26}$. ²⁸⁰This method combines aggregate GWAS summary statistics with tissue-specific gene expression data for targeted tissue enrichment analysis²⁶. Our analysis incorporated 282 various gene sets, including multi-tissue gene expression data from the GTEx project ²⁸³(v8) and chromatin information from the Roadmap Epigenomics and ENCODE 284 initiatives^{26,27}. Using the baseline model and comprehensive gene sets, we prioritized 285 genes from GTEx based on computed t-statistics, focusing on the top 10% of 286 specifically expressed candidate genes that exhibited the highest t-statistics. The ²⁸⁷P-value from the regression coefficient's z-score was used to determine the ²⁸⁸significance coefficient, and a false discovery rate (FDR) of less than 0.05 was 289 applied to assess the significance of enriched SNPs in specific tissues.

290

²⁹¹**Estimating genetic overlap between MAFLD and CVDs**

²⁹²To address the "missing heritability" issue in complex traits, the Genetic Analysis 293 incorporating Pleiotropy and Annotation (GPA) was specifically developed. This tool

²⁹⁴was specifically designed to overcome the limitations posed by the small proportion 295 of genetic variants identified through standard approaches that account for only a 296 minimal part of the expected genetic contribution²⁸. GPA achieves this by integrating ²⁹⁷diverse genomic data and annotation information, thereby enhancing the prioritization 298 of GWAS results and providing a more comprehensive estimation of genetic overlap. ²⁹⁹Notably, in the absence of annotation data, GPA can infer genetic overlap using 300 p-value interactions of the corresponding phenotypes²⁸. GPA is based on key 301 assumptions regarding p-value distributions: p-values from null SNPs are expected to ³⁰²adhere to a uniform distribution, reflecting no association, while p-values from ³⁰³non-null SNPs are presumed to follow a beta distribution, indicating potential 304 associations. Within this framework, GPA categorizes SNPs into four groups based on 305 their p-value characteristics: π 00 suggests no association with either trait; π 01 denotes 306 an association exclusively with the first trait; π 10 signifies an association solely with 307 the second trait; and π 11 represents an association with both traits. This classification 308 can estimate π 11 / (π 10 + π 11 + π 11), an important ratio indicator that represents the 309 proportion of SNPS shared by two traits, suggesting the extent to which a common δ biological pathway may be shared between the two traits²⁸. Subsequently, the 311 likelihood ratio test (LRT) was used to assess the statistical significance of the 312 observed genetic overlap²⁸. Given the complex interrelations among SNPs, GPA ³¹³estimates are susceptible to biases from LD. We used PLINK1.9 for LD pruning to 314 address this, drawing on data from the 1000 Genomes Project Phase 3^{23} for European ³¹⁵ancestry. We also applied a Bonferroni-corrected significance threshold for multiple 316 comparisons, set at $P = 0.05$ / number of trait pairs = 0.05 / $6 = 8.3 \times 10^{-3}$.

--*-*

³¹⁸**Calculating local genetic correlations between MAFLD and CVDs**

LAVA facilitates the assessment of local genetic correlations by partitioning the genome into smaller regions, which enables detailed insights into the influence of 321 genetic variants on various traits at a regional level, rather than across the entire genome²⁹. LAVA analyses genetic correlations within different genomic segments,

323 using the regions delineated by Werme et al. as autosomal LD blocks²⁹, characterized ³²⁴by minimal connectivity between blocks. The genome was partitioned into 2,495 325 semi-independent regions, each approximately 1 Mb, using genotype data from the ³²⁶1000 Genomes Project Phase 3 European ancestry as the LD reference panel and ³²⁷MHC region (chr 6: 25-35 Mb) was excluded. In conducting the genetic association 328 study, we first performed a preliminary univariate analysis using LAVA to estimate the 329 local heritability of MAFLD and CVDs. With this step, we could identify regions that 330 showed significant signals in the local genetic analysis. We then performed bivariate ³³¹LAVA analyses of these regions to explore regional genetic associations between ³³²MAFLD and CVDs. To ensure the statistical significance of the results, the FDR ³³³method was employed to calculate the adjusted p-value. FDR less than 0.05 was 334 considered the genetic correlation of these regions to be statistically significant.

335

³³⁶**Evaluate the causal relationship between MAFLD and CVDs**

The genome-wide and local genetic correlations provide insights into the shared genetic basis between trait pairs, but these correlations do not imply causality in either 339 direction. To overcome these limitations, linkage disequilibrium heterogeneity causal Mendelian randomization (LHC-MR) provides a more refined approach to assess 341 bidirectional causality while minimizing confounding effects³⁰. This method extends 342 traditional MR by addressing limitations of the standard two-sample MR approach, such as potential sample overlap, under-utilization of genome-wide markers, and the need to understand exposure-outcome relationships. LHC-MR assesses bidirectional causality by categorizing associations between exposure and outcome into four 346 categories: (i) causal effect of exposure on outcome, (ii) causal effect of outcome on exposure, (iii) effect of confounders whose exposure affects the outcome process

³⁴⁸(vertical pleiotropy), and (iv) effect of confounders whose exposure affects the 349 outcome independently (horizontal pleiotropy³⁰). Unlike traditional MR, LHC-MR 350 utilizes all genome-wide genetic variation rather than only genome-wide significant 351. variation³⁰. To ensure the stability of the results, the Bonferroni correction significance threshold was set at 4.17×10^{-3} ($P = 0.05$ /number of trait pairs/number of 353 tests). When $P_{\text{av}} < 4.17 \times 10^{-3}$ and $P_{\text{av}} > 0.05$, it suggests a one-way causal relationship from MAFLD to CVD; conversely, when $P_{\text{avx}} < 4.17 \times 10^{-3}$ and $P_{\text{avy}} > 0.05$, 355 it implies a one-way causal relationship from CVD to MAFLD. However, if both P_{axy} 356 and P_{ayx} , exceeding the significance threshold, it indicates bidirectional causality ³⁵⁷between MAFLD and CVD. We used traditional two-sample MR techniques for ³⁵⁸sensitivity analysis, including Inverse Variance Weighting (IVW), MR Egger, ³⁵⁹Weighted Median, Simple Mode, and Weighted Mode. *P*-values below the 0.05 360 threshold were considered statistically significant.

³⁶²**Identification of pleiotropic loci between MAFLD and CVDs**

³⁶³To unravel the shared genetic mechanisms between MAFLD and six major CVDs, our 364 study employs the PLACO, extending pleiotropic analysis to the SNP level³¹. PLACO 365 utilizes the summary statistic from GWAS to calculate the test statistic for the product 366 of the Z-statistics for each SNP in the two trait analyses. This calculation is based on 367 the assumption of a mixed distribution, which allows for the assessment of SNP 368 associations across traits. Using this assumption, PLACO can rigorously analyze ³⁶⁹individual SNPs by pairwise Z-statistics, categorizing the null hypothesis of

378

³⁷⁹**Functional annotation based on pleiotropic loci**

380 To identify and conduct independent genomic loci between MAFLD and six major 381 CVDs, we utilized the Functional Mapping and Annotation (FUMA) platform³². ³⁸²FUMA, an online tool designed to enhance the interpretability of GWAS findings, 383 performs functional annotation of pleiotropic SNPs revealed by PLACO analysis. ³⁸⁴Lead SNPs are merged to delineate distinct genomic loci in LD blocks within 500 kb 385 of lead SNPs by FUMA, utilizing default parameters and LD data from the 1000 386 Genomes Project Phase 3 European cohort. Lead SNP was further selected by r^2 < 0.1 387 for minimal LD in independent significant SNPs (genome-wide significance $P <$ 388 5×10^{-8} and $r^2 < 0.6$), indicating higher independence from adjacent genetic variations. ³⁸⁹Despite these regions potentially containing several lead SNPs, the Top Lead SNP is 390 identified with the lowest P-value within a given region. Locus was deemed novel to ³⁹¹MAFLD and CVD if they did not coincide with the loci previously reported in the

392 original GWAS.

Colocalization analysis

409 After annotating pleiotropic loci using FUMA, we analyzed colocalization with the "COLOC" R package to identify potential shared causal variants across trait pairs 411 within each locus. COLOC analysis employs Bayes factors to evaluate the likelihood 412 of shared causal variation between two sets of trait-associated loci, calculating 413 posterior probabilities (PP) for five mutually exclusive hypotheses at each locus: (i)

422

⁴²³**Gene-level annotation analysis**

⁴²⁴To pinpoint genes that exhibit pleiotropic effects within genomic loci, a Multi-marker ⁴²⁵Analysis of GenoMic Annotation (MAGMA) was performed based on the results of 426 PLACO and individual GWAS³⁶. MAGMA, a tool rooted in multivariable regression ⁴²⁷models, computes the significance of gene-trait associations by incorporating 428 principal component analysis. It then employs the F-test to ascertain p-values for each 429 gene, considering factors such as gene size, SNP count per gene, and LD among the 430 markers. Consistency in gene-based testing was ensured by defining gene boundaries, 431 which encompassed regions extending ± 10 kb from the termini of each gene. We 432 obtained MAGMA gene IDs and location data for 17,636 protein-coding genes, 433 aligning SNP locations with Human Gene Build 37 (GRCh37/hg19). The MHC ⁴³⁴region (chr6: 25-35 Mb) was excluded from MAGMA's gene-based analysis. ⁴³⁵Significant gene associations were identified using a stringent Bonferroni-corrected

436 threshold set at $P = 4.73 \times 10^{-7}$ (0.05 / 17,636 / 6), accounting for the number of 437 protein-coding genes and trait pairs analyzed.

⁴³⁹Recognizing that MAGMA links SNPs to genes based primarily on physical 440 proximity, we extended our analysis to include the eQTL-informed MAGMA 441. (e-MAGMA)³⁷. The e-MAGMA utilizes tissue-specific eQTL data to assign risk ⁴⁴²variants to presumptive genes, thereby converting genome-wide association summary ⁴⁴³statistics into gene-specific metrics. This method leverages tissue-specific eQTL data ⁴⁴⁴from the GTEx project to account for long-range regulatory effects, enhancing the ⁴⁴⁵interpretation of GWAS association signals. MHC region (chr6: 25-35 Mb) was 446 excluded in e-MAGMA analysis results as well as MAGMA to avoid confounding 447 due to complex LD patterns. Our study utilizes the GTEx v8 comprehensive database 448 containing eQTL data from 47 different tissues, based on PLACO results, to delve ⁴⁴⁹into gene-disease associations at a fine-grained tissue level, and to gain a more 450 detailed understanding of the tissue-specific genetic architecture behind the relevant 451 diseases. To minimize confounding factors associated with broad tissue analyses, we 452 refined our approach by selecting a subset of tissues based on insights from ⁴⁵³LDSC-SEG results and previous research. Specifically, our focused analysis included 454 ten tissues: two types of adipose tissue (subcutaneous and visceral omental fat), three ⁴⁵⁵arterial tissues (aorta, coronary, and tibial arteries), two cardiac tissues (left ventricle 456 and atrial appendage), as well as liver, EBV-transformed lymphocytes, and whole ⁴⁵⁷blood. Using the 1000 Genomes Project v3 European samples as the LD reference, we

458 calculated tissue-specific p-values for each gene across the selected tissues. We ⁴⁵⁹applied a Bonferroni correction to determine the significance of these p-values, 460 accounting for the number of tissue-specific protein-coding genes and trait pairs 461 examined. For instance, the significance threshold for adipose subcutaneous tissue 462 was set at $P = 0.05 / 7,560 / 6 = 1.10 \times 10^{-6}$.

⁴⁶⁴To further explore tissue-specific gene-trait associations for MAFLD and CVDs, we ⁴⁶⁵conducted a transcriptome-wide association study (TWAS) using single-trait GWAS 466 results³⁸. Employing the FUSION framework, TWAS integrates GWAS summary 467 statistics with eQTL data from the GTEx v8 dataset to assess how variations in gene ⁴⁶⁸expression across specific tissues influence phenotypes. We used pre-computed gene ⁴⁶⁹expression weight references from the tissues analyzed in our e-MAGMA study. LD 470 pruning was performed during the third phase of the 1000 Genomes Project using the 471 LD structures of the European subpopulation. Significance thresholds were adjusted 472 using tissue-specific Bonferroni corrections to control for multiple tests.

⁴⁷⁴**Pathway level analyses**

⁴⁷⁵We performed functional enrichment analysis on the overlapped gene lists 476 significantly identified by MAGMA and e-MAGMA analyses using the ToppGene 477 functional annotation tool (ToppFun)³⁹. ToppGene Suite is a comprehensive portal for 478 gene list enrichment analysis and candidate gene prioritization. The ToppFun 479 application provides a variety of annotation data types, including transcriptome,

⁴⁸⁷**Results**

⁴⁸⁸**SNP-based heritability and genetic correlations between MAFLD and CVDs**

⁴⁸⁹After harmonizing and filtering SNPs common across GWAS summary statistics, 490 LDSC was utilized to estimate the h^2_{SNP} and the genome-wide genetic correlations (r_g) 491 between MAFLD and CVDs. Univariate LDSC analysis indicated that the h^2_{SNP} of 492 MAFLD was 0.002 (SE = 0.001). In comparison, the h^2_{SNP} of CVDs ranged from 493 0.008 to 0.032, with CAD exhibiting the highest heritability ($h^2_{SNP} = 0.032$, SE = 494 1.90 \times 10⁻³) and HF the lowest ($h^2_{SNP} = 0.008$, SE = 3.01 \times 10⁻³). Notably, the 495 heritability of MAFLD was lower than that of any individual CVD. Bivariate LDSC 496 revealed that all trait pairs exhibited positive genetic correlations under a relaxed 497 significance threshold $(P < 0.05)$. However, four trait pairs maintained statistical 498 significance after applying a Bonferroni correction for multiple comparisons ($P <$ 499 0.05 / $6 = 8.33 \times 10^{-3}$). These findings highlight the subtle genetic interactions between ⁵⁰⁰MAFLD and CVD, which underscores the potential for shared genetic pathways to 501 influence these complex diseases.

502

⁵⁰³**Genetic overlap analysis**

504 The r_g is a vital metric that reflects the genetic relationship between trait pairs, 505 providing insights into their shared genetic architecture. Importantly, a r_g value close 506 to zero does not necessarily signify the absence of a genetic association between traits. ⁵⁰⁷This apparent discrepancy can arise from various factors, such as the mixed effects of ⁵⁰⁸homozygosity and reverse effects, or a lack of genetic overlap, which may mask the 509 true genetic relationships and lead to misleadingly low r_g values. Recognizing this 510 limitation highlights a "missing dimension" in our understanding of genetic 511 connections between phenotypes. To enhance our understanding of genetic 512 interactions and address these challenges, advanced statistical methods, including 513 GPA and LAVA, have been employed by us.

515 The intricacies of the genetic relationships observed between MAFLD and CVDs, 516 particularly the surprising contrast between significant genetic overlap and weak 517 correlation in some cases, underscore the complexity of genetic interactions and the 518 importance of considering additional analytical dimensions. In our analysis of six trait 519 pairs, the MAFLD-AF pair was the only one that failed to meet the Bonferroni 520 correction threshold, indicating a lack of significant genetic overlap. Conversely, the ⁵²¹MAFLD-CAD pair demonstrated the most significant genetic overlap, evidenced by a 522 P-value of 7.12×10^{-31} , aligning with LDSC results, which revealed the highest genetic 523 correlation ($r_g = 0.627$, $P = 5.18 \times 10^{-6}$). Although a significant genetic overlap was

524 identified between MAFLD and Stroke $(P = 6.96 \times 10^{-6})$, the minimal PAR value (PAR $= 7.00\times10^{-4}$) highlights a small proportion of pleiotropic SNPs. Furthermore, the weak 526 genetic correlation between MAFLD and Stroke ($r_g = 0.627$, $P = 3.98 \times 10^{-2}$) suggests 527 that the presence of multiple closely linked SNPs with independent or heterogeneous 528 impacts may obscure consistent effects, resulting in a correlation that falls short of 529 higher statistical confidence thresholds. This phenomenon, where broad genetic 530 overlap coexists with weak genetic correlation, implies that mixed effects may mask 531 the true genome-wide genetic correlation.

532

⁵³³**Regional genetic correlation analysis**

⁵³⁴LAVA evaluates genetic correlations within specific genomic regions and identifies 535 subtle genetic effects that might elude detection by LDSC. This capability is vital, as 536 genetic influences often vary across the genome, and the correlations between traits 537 can differ markedly by region. First, a univariate LAVA analysis was conducted by us 538 with a strict threshold of $P < 1 \times 10^{-4}$ to identify regions with strong genetic signals, 539 resulting in the identification of 2,336 significant regions. These regions were then 540 formed into 77 bivariate test sets for more detailed analysis. In the subsequent 541 bivariate LAVA analysis, we applied a looser significance threshold $(P < 0.05)$, 542 identifying approximately 22 genomic regions showing genetic signals associated 543 with all trait pairs. Notably, our LAVA analysis revealed five key genetic regions ⁵⁴⁴associated with MAFLD and stroke, including three negatively and two positively 545 correlated regions. This discovery of substantial genetic overlap starkly contrasts the

556

⁵⁵⁷**Causal relationship linking MAFLD and CVDs**

558 The observed genetic overlap between MAFLD and CVDs extends beyond mere 559 correlation, suggesting the presence of pleiotropy. However, determining whether this 560 pleiotropy is horizontal or vertical remains unresolved. To clarify this, we utilized the ⁵⁶¹LHC-MR approach, which sheds light on the bidirectional causal relationships 562 between MAFLD and CVD through vertical pleiotropy. Our findings revealed a 563 significant positive causal effect of MAFLD on both AF and PAD, with odds ratios 564 (OR) of 1.11 ($P = 2.36 \times 10^{-3}$) and 1.375 ($P = 1.39 \times 10^{-4}$), respectively. These results 565 underscore MAFLD as a critical risk factor in the onset and development of both AF 566 and PAD, aligning with previous research that highlights MAFLD's role in increasing 567 the prevalence of these disorders. Notably, we found no evidence to suggest reverse

568 causality in these relationships.

569

⁵⁷⁰**Shared variants and functional annotation of MAFLDs and CVDs**

571 To further dissect the complex genetic mechanisms between MAFLD and CVDs, we ⁵⁷²utilized PLACO to identify significant pleiotropic variants indicative of horizontal 573 pleiotropy. This inquiry, through its meticulous analysis, unveiled a trove of 3,438 ⁵⁷⁴SNPs exhibiting significant pleiotropic influences. Subsequently, these SNPs 575 underwent a process of annotation, facilitated by the FUMA tool, which meticulously 576 delineated 49 distinct loci spanning 20 chromosomal regions, enriching our 577 understanding of the genetic landscape under scrutiny. Seven of the 49 loci identified 578 were novel and had not been previously associated with MAFLD or CVDs. Among 579 the 22 loci (44.9%), the selected effect alleles at the top SNPs within or near loci 580 demonstrated effect directions that were consistent with each other which means they 581 may concurrently increase ADs and CVDs or diminish the risk of developing ADs and ⁵⁸²CVDs. Notably, three loci, 22q13.31, 16q12.2, and 8q24.13, were associated with 583 more than half of the trait pairs analyzed. The chromosomal region 22q13.31, in 584 particular, is implicated in five trait pairs, excluding MAFLD-Stroke, highlighting its 585 significance in the pleiotropic landscape. For example, *SAMM50* located at 22q13.31, 586 studies have shown that *SAMM50* gene polymorphisms are associated with the 587 occurrence and severity of fatty liver disease, which may be related to reduced fatty 588 acid oxidation caused by *SAMM50* deficiency⁴⁰. Although there is no direct evidence 589 linking *SAMM50* to cardiovascular disease, its potential effects on heart development

600

⁶⁰¹Functional annotation via FUMA identified 24 intronic SNPs, 14 intergenic SNPs, 602 and 5 exonic SNPs. For example, the $22q13.31$ region includes the exonic SNP ⁶⁰³rs1007863, which showed significant eQTL associations in several tissues: adipose 604 subcutaneous ($P = 2.38 \times 10^{-6}$), adipose visceral omentum ($P = 2.16 \times 10^{-15}$), whole 605 blood ($P = 3.57 \times 10^{-5}$), artery aorta ($P = 3.57 \times 10^{-5}$), and artery tibial ($P = 1.42 \times 10^{-12}$). 606 Notably, the P-value for adipose visceral omentum was used as the P-value for this 607 region in MAFLD-AF for PLACO results, indicating that this P-value is considered 608 the most appropriate or representative indicator, suggesting that visceral tissues are 609 importantly associated with this trait pair. Seven of all pleiotropic SNPs were 610 identified as potentially deleterious, with a CADD score greater than 12.37. Notably, 611 rs28929474 exhibited the highest CADD score of 20.2, suggesting its potential

619

⁶²⁰**Gene-level annotation of MAFLD and CVDs**

621 Using MAGMA, we identified 34 potential pleiotropic genes (28 of which are unique) 622 between MAFLD and CVDs after Bonferroni correction, which is situated on or 623 overlaps with 49 previously identified pleiotropic loci. Among these, 2 are novel ⁶²⁴unique genes, 3 have newly unique been associated with CVDs, and 23 are newly ⁶²⁵unique implicated in MAFLD. Notably, three genes—*SAMM50*, PNPLA3, and ⁶²⁶*FTO*—were detected in two or more trait pairs. Further, of the genes identified by 627 MAGMA, 32 were corroborated by FUMA's locus mapping. The pervasive impact of ⁶²⁸*SAMM50* across multiple traits underscores its significance and makes it a primary 629 focus of our ongoing investigation.

630

⁶³¹We performed tissue-specific analyses employing LDSC-SEG to identify the tissues 632 associated with each disease. After adjusting for multiple comparisons using the FDR ⁶³³method, significant associations were observed solely with CVDs. Specifically, for AF,

⁶³⁴the auricle and the left ventricle were identified as the primary tissues driving the ⁶³⁵condition, suggesting that functional changes in these areas may play a crucial role in 636 its development and maintenance. Similarly, in CAD, the predominant tissues ⁶³⁷associated with the disease were located in arterial regions, including the aorta, ⁶³⁸coronary artery, and anterior tibial artery, with the anterior tibial artery demonstrating 639 the most significant impact. Unfortunately, while MAFLD showed enrichment in the 640 anterior cingulate cortex, cerebral cortex, and frontal cortex, these did not meet the 641 significant threshold for correction. In all, afte integrating the results of tissue 642 enrichment analysis with tissues commonly implicated in clinical practice for these 643 conditions, we finally selected 10 tissues for subsequent analysis.

644

⁶⁴⁵Given the limitations of MAGMA, which assigns SNPs based solely on proximity to ⁶⁴⁶genes and may overlook the effects of distant gene regulation, we employed ⁶⁴⁷e-MAGMA to overcome these deficiencies. By integrating eQTL data from 10 648 distinct tissues, e-MAGMA enabled us to identify 161 tissue-specific genes, including ⁶⁴⁹59 that were unique. Notably, *IRAK1BP1*, *ATP13A1*, *SAMM50* and *NME7* were 650 identified in more than half of the trait pairs. *IRAK1BP1* exhibits high specificity to 651 nine tissues except EBV-transformed lymphocytes and has not previously been ⁶⁵²associated with MAFLD or any CVDs. However, its involvement in inflammation 653 suggests a potential role in these diseases. Our findings were further validated using ⁶⁵⁴FUMA's GTExV8 data through e-MAGMA, confirming the identification of 78 655 tissue-specific genes, including *SAMM50* at 22q13.31. Subsequent TWAS analysis of

664

⁶⁶⁵**Functional enrichment analysis of pleiotropic genes in MAFLD and CVDs**

⁶⁶⁶Understanding how identified genes collectively fulfill specific biological functions 667 through shared pathways enhances our ability to derive meaningful interpretations ⁶⁶⁸from genomic data. The tool ToppFun assists in mapping these genes to their ⁶⁶⁹respective enrichment pathways and biological processes, which can reveal the 670 activity levels or enrichment of certain pathways. Notably, three pathways were 671 significantly enriched: membrane organization, endoplasmic reticulum tubular 672 network organization, and the establishment of protein localization to the membrane. 673 Protein localization is critical in the accumulation of lipid droplets near mitochondria; ⁶⁷⁴it helps protect mitochondrial function by sequestering toxic lipids. This protective 675 mechanism is crucial for managing lipid accumulation in the liver and other tissues, 676 where excessive lipid buildup can lead to MAFLD and CVDs^{47,48}. Proper protein ⁶⁷⁷localization, therefore, plays a pivotal role in mitigating lipid toxicity and maintaining

678 cellular balance, thereby reducing the risk of both MAFLD and CVD.

⁶⁸⁰**Discussion**

681 This genome-wide pleiotropic association study offers compelling evidence of a 682 shared genetic architecture and mechanisms between MAFLD and six major CVDs. ⁶⁸³We observed moderate to strong genome-wide genetic associations between MAFLD 684 and four CVDs—CAD, HF, PAD, and VTE—with notable genetic overlap in all but 685 the MAFLD-AF trait pair. MR analysis provided evidence of causal relationships for 686 two trait pairs, underscoring the presence of vertical pleiotropy. Additionally, at the ⁶⁸⁷SNP level, our cross-trait analysis pinpointed 49 pleiotropic loci, 13 demonstrating 688 strong evidence of colocalization. Further analysis at the gene level through MAGMA ⁶⁸⁹and e-MAGMA identified 45 (34 unique) significant position-specific pleiotropic ⁶⁹⁰genes and 161 (59 unique)tissue-specific pleiotropic genes, including 17 overlapping 691 pleiotropic genes (14 unique because *SAMM50* was identified in 4 trait pairs). ⁶⁹²Moreover, at the biological pathway level, protein localization to membrane signaling 693 pathways was identified as potentially pivotal in the co-pathogenesis of MAFLD and ⁶⁹⁴CVD. These insights not only deepen our understanding of their intertwined genetic 695 etiology but also illuminate potential targets for therapeutic intervention and 696 preventive strategies.

697

⁶⁹⁸In our study, bivariate LDSC revealed extensive positive genetic correlations between ⁶⁹⁹MAFLD and six major CVDs, among which only four trait pairs (including

⁷⁰⁰MAFLD-CAD, MAFLD-HF, MAFLD-PAD, and MAFLD-VTE) passed the ⁷⁰¹Bonferroni correction. Further analysis using the GPA method demonstrated 702 significant genetic overlap for all pairs except MAFLD with AF, underscoring the ⁷⁰³shared genetic underpinnings of these conditions. Interestingly, although no 704 significant genome-wide genetic correlation was detected between MAFLD and ⁷⁰⁵stroke, substantial genetic overlap suggested the presence of complex genomic 706 interactions, which was also confirmed by local genetic correlations of LAVA. In the ⁷⁰⁷MAFLD-stroke pair, we identified loci with mixed effect directions—two positively 708 and three negatively correlated—suggesting that local mixed effects might underlie 709 the non-significant genome-wide genetic correlation, potentially driven by a range of 710 pleiotropic variants¹¹. Additionally, despite the lack of a significant association 711 between MAFLD and AF in both LDSC and GPA analyses, our bivariate LAVA under ⁷¹²a loose threshold indicated a positive regional genetic correlation between the two. 713 Overall, our findings confirm that MAFLD and CVDs share substantial heritability ⁷¹⁴and genetic components, elucidating the genetic basis of their high comorbidity.

716 The shared genetic basis between MAFLD and CVD is primarily driven by horizontal 717 and vertical pleiotropy (i.e., causal relationships). We employed the LHC-MR method 718 to investigate potential causal links between MAFLD and 6 major CVDs. Our 719 analysis revealed that genetically predicted MAFLD is causally associated with an 720 increased risk of AF and PAD. These findings are consistent with prior ⁷²¹epidemiological evidence. A meta-analysis confirmed an association between

739 Horizontal pleiotropy analysis further elucidated the common genetic architecture 740 between MAFLD and CVD by discovering pleiotropic variants and loci, pleiotropic 741 genes, and biological pathways between the two. Further investigation through 742 horizontal pleiotropy analysis has confirmed their extensive comorbidity, identifying 743 widespread pleiotropic variants across several key loci, such as 22q13.31, 16q12.2,

759 In our gene-level analysis using MAGMA and e-MAGMA, we identified significant pleiotropic genes at the $22q13.31$ locus, including patatin-like phospholipase-domain 761 containing protein 3 (*PNPLA3*) and sorting and assembly machinery component 50 (*SAMM50*). These genes play crucial roles in the comorbidity between MAFLD and 763 CVDs. PNPLA3, which exhibits weak hydrolytic activity towards glycerolipids, has 764 been linked to the development of MAFLD and CVDs, excluding PAD and Stroke. 765 This gene is associated with a missense variant closely linked to triacylglycerol (TAG)

786 In our pathway-level analysis, we discovered a crucial role for the gene *SAMM50* in 787 mediating protein localization to membranes, a process integral to the pathogenesis of

⁷⁸⁸MAFLD. This protein localization is especially important in how lipid droplets 789 accumulate near mitochondria, which may protect mitochondrial function by 790 sequestering toxic lipid species. Proteins that migrate to these lipid droplets at ⁷⁹¹membrane contact sites are prime candidates for facilitating this protective 792 mechanism^{47,48}. In the liver, an excessive influx of lipids leads to the accumulation of 793 triglyceride (TG)-rich lipid droplets, a hallmark of MAFL D^{47} . Variations in genes 794 associated with lipid droplet formation, such as PNPLA3, acting as both 795 phospholipase and acyl transfer enzyme, is an important regulating factor for TG. It 796 limits the activity of triglyceride hydrolases, leading to TG accumulation in the liver, 797 thus predisposing to MAFLD⁵⁸. Moreover, when lipid droplets amass in peripheral 798 organs, the overflow of toxic lipids can contribute to CVDs. ATGL plays a pivotal role 799 in this context by hydrolyzing TG within these droplets. It activates the ⁸⁰⁰PPARα/peroxisome proliferator-activated receptor-γ coactivator 1 (*PGC1*) complex in 801 cardiomyocytes. A deficiency in cardiac ATGL leads to reduced *PGC1* expression, ⁸⁰²resulting in mitochondrial dysfunction and lipid accumulation, which can progress to $H F⁵⁹$. In conclusion, the localization of contact site proteins related to lipid droplets is 804 instrumental in preventing lipid overflow and safeguarding mitochondrial function. 805 This mechanism significantly reduces the risk of both MAFLD and CVD by 806 maintaining crucial cellular balances and interactions.

807

⁸⁰⁸Our study has several limitations. First, our study population was confined to 809 individuals of European ancestry, necessitating further research across other ethnic

818

819 In summary, our study demonstrates extensive genetic overlap, partial genetic 820 correlation, and causal relationships between MAFLD and six major CVDs. 821 Identification of the pleiotropic gene, *SAMM50*, at pleiotropic risk loci 22q13.31, 822 shared between MAFLD and CVD, suggesting a common biological mechanism, 823 namely the establishment of protein localization to the membrane, uncovering 824 indications of shared genetic foundation for MAFLD and CVDs. This research 825 enhances the shared genetic map of these diseases and offers new perspectives on 826 preventing and treating their co-morbidities.

Abbreviations

856

⁸⁵⁷**Acknowledgements**

⁸⁵⁸We would like to thank all GWAS authors who provided summary statistics for this 859 study. We thank the Electronic Medical Records and Genomics (eMERGE) Network, 860 the UK Biobank (UKB), the Estonian Biobank (EstBB), and the FinnGen Consortium 861 for providing us with data on MAFLD, without whom this work would not have been 862 possible. We would also like to thank the Health Study Nord-Trøndelag (HUNT), 863 deCODE, Michigan Genome Initiative (MGI), DiscovEHR, UKB, and AFGen 864 consortium for providing AF data; the CARDIoGRAMplusC4D and UKB consortium 865 for providing CAD data; the deCODE for providing VTE data; the Heart Failure ⁸⁶⁶Molecular Epidemiology for Therapeutic Targets (HERMES) consortium for 867 providing HF data; the Cardiovascular Disease Knowledge Portal (CVDKP) website 868 for providing PAD data; and the GIGASTROKE consortium for providing stroke 869 data.

870

⁸⁷¹**References**

- ⁸⁷²[1] Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et
- 873 al. A new definition for metabolic dysfunction-associated fatty liver disease: An
- 874 international expert consensus statement. J Hepatol 2020; 73: 202-9.
- ⁸⁷⁵[2] Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed
- 876 Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020;
- 877 158: 1999-2014.e1.
- 878 [3] Sanyal AJ, Castera L, Wong VW. Noninvasive Assessment of Liver Fibrosis in
- 879 NAFLD. Clin Gastroenterol Hepatol 2023; 21: 2026-39.
- ⁸⁸⁰[4] Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related 881 mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.
- 882 [5] Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to
- 883 cardiovascular disease. Mol Metab 2020; 42: 101092.
- 884 [6] Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and
- ⁸⁸⁵cardiovascular diseases: a clinical review. Clin Res Cardiol 2021; 110: 921-37.
- 886 [7] Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver
- 887 disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016;
- ⁸⁸⁸65: 589-600.
- ⁸⁸⁹[8] Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al.
- ⁸⁹⁰Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic
- 891 steatohepatitis from cardiovascular disease. Hepatology 2015; 61: 506-14.
- ⁸⁹²[9] Brouwers M, Simons N, Stehouwer CDA, Koek GH, Schaper NC, Isaacs A.

- 894 Coronary Artery Disease. Hepatol Commun 2019; 3: 587-96.
- ⁸⁹⁵[10] Fang Z, Jia S, Mou X, Li Z, Hu T, Tu Y, et al. Shared genetic architecture and
- 896 causal relationship between liver and heart disease. iScience 2024; 27: 109431.
- ⁸⁹⁷[11] Hindley G, Frei O, Shadrin AA, Cheng W, O'Connell KS, Icick R, et al. Charting
- 898 the Landscape of Genetic Overlap Between Mental Disorders and Related Traits
- 899 Beyond Genetic Correlation. Am J Psychiatry 2022; 179: 833-43.
- ⁹⁰⁰[12] Perry BI, Bowker N, Burgess S, Wareham NJ, Upthegrove R, Jones PB, et al.
- ⁹⁰¹Evidence for Shared Genetic Aetiology Between Schizophrenia, Cardiometabolic, and
- 902 Inflammation-Related Traits: Genetic Correlation and Colocalization Analyses.
- 903 Schizophr Bull Open 2022; 3: sgac001.
- ⁹⁰⁴[13] Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy
- 905 in Mendelian randomization studies. Hum Mol Genet 2018; 27: R195-r208.
- ⁹⁰⁶[14] Ren Z, Simons P, Wesselius A, Stehouwer CDA, Brouwers M. Relationship
- 907 between NAFLD and coronary artery disease: A Mendelian randomization study.
- 908 Hepatology 2023; 77: 230-8.
- ⁹⁰⁹[15] Peng H, Wang S, Wang M, Ye Y, Xue E, Chen X, et al. Nonalcoholic fatty liver
- 910 disease and cardiovascular diseases: A Mendelian randomization study. Metabolism 911 2022; 133: 155220.
- ⁹¹²[16] Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, et al. Electronic ⁹¹³health record-based genome-wide meta-analysis provides insights on the genetic 914 architecture of non-alcoholic fatty liver disease. Cell reports Medicine 2021; 2:

936 global reference for human genetic variation. Nature 2015; 526: 68-74.

- ⁹³⁷[24] Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al.
- ⁹³⁸LD Score regression distinguishes confounding from polygenicity in genome-wide
- 939 association studies. Nature genetics 2015; 47: 291-5.
- ⁹⁴⁰[25] Zhang Y, Qi G, Park JH, Chatterjee N. Estimation of complex effect-size
- 941 distributions using summary-level statistics from genome-wide association studies
- 942 across 32 complex traits. Nature genetics 2018; 50: 1318-26.
- ⁹⁴³[26] Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, et al.
- ⁹⁴⁴Heritability enrichment of specifically expressed genes identifies disease-relevant
- 945 tissues and cell types. Nature genetics 2018; 50: 621-9.
- ⁹⁴⁶[27] Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis:
- 947 multitissue gene regulation in humans. Science (New York, NY) 2015; 348: 648-60.
- 948 [28] Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to
- 949 prioritizing GWAS results by integrating pleiotropy and annotation. PLoS genetics
- 950 2014; 10: e1004787.
- ⁹⁵¹[29] Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework
- 952 for local genetic correlation analysis. Nature genetics 2022; 54: 274-82.
- ⁹⁵³[30] Darrous L, Mounier N, Kutalik Z. Simultaneous estimation of bi-directional
- 954 causal effects and heritable confounding from GWAS summary statistics. Nature 955 communications 2021; 12: 7274.
- ⁹⁵⁶[31] Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite
- 957 null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate
- 958 Cancer. PLoS genetics 2020; 16: e1009218.

- ⁹⁶²[33] Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general
- ⁹⁶³framework for estimating the relative pathogenicity of human genetic variants. Nature
- 964 genetics 2014; 46: 310-5.
- ⁹⁶⁵[34] Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al.
- ⁹⁶⁶Annotation of functional variation in personal genomes using RegulomeDB. Genome
- 967 research 2012; 22: 1790-7.
- ⁹⁶⁸[35] Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
- 969 variants from high-throughput sequencing data. Nucleic acids research 2010; 38: 970 e164.
- ⁹⁷¹[36] de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set
- 972 analysis of GWAS data. PLoS computational biology 2015; 11: e1004219.
- ⁹⁷³[37] Gerring ZF, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an
- ⁹⁷⁴eQTL-informed method to identify risk genes using genome-wide association study
- 975 summary statistics. Bioinformatics (Oxford, England) 2021; 37: 2245-9.
- 977 causal variants by statistical fine-mapping. Nature reviews Genetics 2018; 19: 978 491-504.

⁹⁷⁶[38] Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate

⁹⁷⁹[39] Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list 980 enrichment analysis and candidate gene prioritization. Nucleic acids research 2009;

981 37: W305-11.

- ⁹⁸²[40] Li Z, Shen W, Wu G, Qin C, Zhang Y, Wang Y, et al. The role of SAMM50 in
- 983 non-alcoholic fatty liver disease: from genetics to mechanisms. FEBS Open Bio 2021;

984 11: 1893-906.

- ⁹⁸⁵[41] Xu R, Kang L, Wei S, Yang C, Fu Y, Ding Z, et al. Samm50 Promotes
- ⁹⁸⁶Hypertrophy by Regulating Pink1-Dependent Mitophagy Signaling in Neonatal
- 987 Cardiomyocytes. Front Cardiovasc Med 2021; 8: 748156.
- ⁹⁸⁸[42] Patnaik D, Jena AB, Kerry RG, Duttaroy AK. In silico profiling of
- 989 nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on
- 990 the treatment of non-alcoholic fatty liver disease. Lipids Health Dis 2023; 22: 17.
- ⁹⁹¹[43] Xu ZY, Jing X, Xiong XD. Emerging Role and Mechanism of the FTO Gene in
- 992 Cardiovascular Diseases. Biomolecules 2023; 13.
- ⁹⁹³[44] Bauer RC, Yenilmez BO, Rader DJ. Tribbles-1: a novel regulator of hepatic lipid
- 994 metabolism in humans. Biochem Soc Trans 2015; 43: 1079-84.
- 995 [45] Zhang T, Tan P, Wang L, Jin N, Li Y, Zhang L, et al. RNALocate: a resource for
- 996 RNA subcellular localizations. Nucleic acids research 2017; 45: D135-d8.
- ⁹⁹⁷[46] Jiang J, Chen X, Li C, Du X, Zhou H. Polymorphisms of TRIB1 genes for
- 998 coronary artery disease and stroke risk: A systematic review and meta-analysis. Gene 999 2023; 880: 147613.
- ¹⁰⁰⁰[47] Krahmer N, Najafi B, Schueder F, Quagliarini F, Steger M, Seitz S, et al.
- 1001 Organellar Proteomics and Phospho-Proteomics Reveal Subcellular Reorganization in
- 1002 Diet-Induced Hepatic Steatosis. Dev Cell 2018; 47: 205-21.e7.

- ¹⁰⁰⁴DGAT1-Dependent Lipid Droplet Biogenesis Protects Mitochondrial Function during
- 1005 Starvation-Induced Autophagy. Dev Cell 2017; 42: 9-21.e5.
- ¹⁰⁰⁶[49] Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of
- 1007 cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic
- 1008 review and meta-analysis. Eur J Prev Cardiol 2022; 29: 938-46.
- ¹⁰⁰⁹[50] Ciardullo S, Bianconi E, Cannistraci R, Parmeggiani P, Marone EM, Perseghin G.
- ¹⁰¹⁰Peripheral artery disease and all-cause and cardiovascular mortality in patients with
- 1011 NAFLD. J Endocrinol Invest 2022; 45: 1547-53.
- ¹⁰¹²[51] Guo J, Ren W, Li A, Ding Y, Guo W, Su D, et al. Fat mass and obesity-associated
- 1013 gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. Dig
- 1014 Dis Sci 2013; 58: 1004-9.
- ¹⁰¹⁵[52] Liu C, Mou S, Pan C. The FTO gene rs9939609 polymorphism predicts risk of
- 1016 cardiovascular disease: a systematic review and meta-analysis. PLoS One 2013; 8: 1017 e71901.
- ¹⁰¹⁸[53] Doney AS, Dannfald J, Kimber CH, Donnelly LA, Pearson E, Morris AD, et al. ¹⁰¹⁹The FTO gene is associated with an atherogenic lipid profile and myocardial 1020 infarction in patients with type 2 diabetes: a Genetics of Diabetes Audit and Research 1021 Study in Tayside Scotland (Go-DARTS) study. Circ Cardiovasc Genet 2009; 2: 255-9.
- ¹⁰²²[54] Witzel HR, Schwittai IMG, Hartmann N, Mueller S, Schattenberg JM, Gong XM,
- 1023 et al. PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with
- 1024 ATGL. Cells 2022; 12.

- ¹⁰²⁸[56] Simons N, Isaacs A, Koek GH, Kuč S, Schaper NC, Brouwers M. PNPLA3,
- 1029 TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease. Gastroenterology
- 1030 2017; 152: 912-3.
- ¹⁰³¹[57] Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al.
- 1032 Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and
- 1033 PARVB genes are associated with development and progression of nonalcoholic fatty
- 1034 liver disease in Japan. Hum Genet 2013; 132: 783-92.
- ¹⁰³⁵[58] Dai G, Liu P, Li X, Zhou X, He S. Association between PNPLA3 rs738409
- 1036 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and
- 1037 severity: A meta-analysis. Medicine 2019; 98: e14324.
- ¹⁰³⁸[59] Krahmer N, Farese RV, Jr., Walther TC. Balancing the fat: lipid droplets and
- 1039 human disease. EMBO Mol Med 2013; 5: 973-83.

Table 1. Genetic Correlation and Genetic Overlap Estimations Between 6

Note:

Pairwise Traits^a

a. Genetic correlation and genetic overlap were estimated by LDSC and GPA methods, respectively. Bonferroni-corrected significance threshold was set at $P\square \le 8.33\times10^{-3}$ (0.05/6), producing a final union set of 5 pairwise traits with significant genetic correlation or genetic overlap for subsequent analysis.

b. We introduced PAR as PM 11 / (PM $10 + PM$ 01 + PM 11) to represent the proportion of pleiotropic single-nucleotide variations (SNPs) associated with both traits against the proportion of SNPs associated with at least 1 trait.

c. Pairwise trait with significant genetic correlation.

d. Pairwise trait with significant genetic overlap.

Abbreviations: MAFLD, Metabolic dysfunction-Associated fatty liver disease; AF, Atrial fibrillation; CAD, Coronary artery disease; HF, Heart failure; PAD, Peripheral artery disease; VTE, Venous thromboembolism; LDSC, linkage disequilibrium score regression; GPA, genetic analysis incorporating pleiotropy and annotation method; PAR, pleiotropy association ratio; PM 11, proportion of genetic variants associated with both traits.

Figure legends

Figure 1. Metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases estimated by local genetic correlation.

LAVA volcano plots showing local genetic correlation coefficients (local- $r_{\rho}s$, y-axis) for MAFLD and CVDs with -log10 *p*-values for each trait pair of analyses for each locus. Loci above the horizontal line are significant at $P < 0.05$ (negative correlation for blue dots, positive correlation for red dots). Larger points with black circles indicate loci significantly associated after Bonferroni correction ($P = 6.49 \times 10^{-4} = 0.05$) / 77). LAVA-estimated local-rgs is shown on the blue-red scale. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

Figure 2. Inference of bidirectional causal relationship between metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.

Forest plots of the causal relationship between MAFLD and six major CVDs using the LHC-MR method. The estimates presented in the forest plot were obtained using the LHC-MR method. A positive association is indicated by the odd ratio ($OR > 1$), while a negative association is indicated by $OR < 1$. The results of forward causality from the LHC-MR method are in the up panel, and the results of reverse causality from the LHC-MR method are in the down panel. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

Figure 3. Manhattan plots for the PLACO results of metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.

Manhattan plots reflect chromosomal position (x-axis) and negative log10-transformed P-values (y-axis) for each SNP. The horizontal dashed red line indicates the genome-wide significant P-value of -log10 (5×10^{-8}). The r² threshold for defining independent significant SNPs was set to 0.2, and the maximum distance between LD blocks merged into one locus was set to 500 kb. The independent genome-wide significant associations with the smallest P-value (Top lead SNP) are encircled in a colorful circle. Only SNPs shared across all summary statistics were included. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

Figure 4. The overall situation of the pleiotropy association between metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.

A circular dendrogram showing the shared genes between MAFLD (center circle) and each of six CVDs (first circle), resulting in six pairs. A total of 49 shared loci were identified across six trait pairs (third circle), mapped to 45 nominally significant pleiotropic genes (34 were Bonferroni-corrected significant) identified by

> multimarker analysis of GenoMic annotation (MAGMA). For the trait pairs with more than three pleiotropic genes, we only showed the top 3 pleiotropic genes according to the prioritization of candidate pleiotropic genes (fourth circle). MAFLD, metabolic dysfunction-associated fatty liver disease; AF, Atrial fibrillation; CAD, Coronary artery disease; VTE, Venous thromboembolism; HF, Heart failure; PAD, Peripheral artery disease.

Figure 2.

Lower Risk Higher Risk

Figure 4.

